Antibodies
2 December 2009
Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial1 December 2009
Bayer Schering Pharma to collaborate with Micromet on novel approach to cancer therapy30 November 2009
Xencor Licenses Antibody Optimization Technology24 November 2009
Seattle Genetics and Agensys, an Affiliate of Astellas, Expand Antibody-Drug Conjugate Collaboration23 November 2009
Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis23 November 2009
GLYCOTOPE receives regulatory approval for GlycoExpress Technology and initiates first clinical trial with lead antibody GT-MAB 2.5 GEX20 November 2009
ACTEMRA Improves Signs and Symptoms in Children with Systemic Onset Juvenile Idiopathic Arthritis (sJIA)20 November 2009
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Company’s TAP Technology18 November 2009
Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic Leukemia17 November 2009
Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast Cancer17 November 2009
HUMAN GENOME SCIENCES RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR RAXIBACUMAB BIOLOGICS LICENSE APPLICATION17 November 2009
ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma16 November 2009
Human Genome Sciences Receives Complete Response Letter from FDA for Raxibacumab Biologics License Application16 November 2009
BioInvent and ThromboGenics Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients with Advanced Solid Tumours13 November 2009
BioInvent signs licensing agreement with Daiichi Sankyo for the discovery and development of therapeutic antibodies9 November 2009
MorphoSys Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MOR103 Program9 November 2009
Anti-Malignancy Agent Avastin® Obtained Approval for Additional Indication of Non-Small Cell Lung Cancer5 November 2009
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer3 November 2009
FibroGen Announces New Research in Anti-CTGF and HIF-PHI3 November 2009
Calmune and Crucell Enter Exclusive Research Collaboration3 November 2009
XOMA Signs Antibody Discovery Collaboration With KaketsukenNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports